IL1B and systemic-onset juvenile idiopathic arthritis: Biological drugs—inhibitors of IL-1β and IL-6 receptors—approved for the treatment of children with sJIA over two years old [2] according to the modern treatment paradigm of this disease, «treat-to-target,» are highly effective in patients with sJIA [3]; however, they could increase the risk of infectious diseases.